| Literature DB >> 35640809 |
Gustavo Olaiz-Fernández1, Félix Jesús Vicuña de Anda1, Jorge-Baruch Diaz-Ramirez2, German E Fajardo Dolci3, Patricia Bautista-Carbajal4, Antonio Humberto Angel-Ambrocio4, Miguel Leonardo García-León4, Elena Gómez Peña1, Jorge Alejandro Camacho Morales5, Rosa Maria Wong-Chew6.
Abstract
INTRODUCTION: SARS-CoV-2 continues to have a high rate of contagion worldwide. The new variant of concern, Omicron, has mutations that decrease the effectiveness of vaccines and evade antibodies from previous infections resulting in a fourth wave of the pandemic. It was identified in Mexico in December 2021.Entities:
Keywords: Asymptomatic infections; COVID-19 testing; Epidemiologic factors; Pandemics; Travel medicine; Travel-related illness
Mesh:
Year: 2022 PMID: 35640809 PMCID: PMC9148423 DOI: 10.1016/j.tmaid.2022.102361
Source DB: PubMed Journal: Travel Med Infect Dis ISSN: 1477-8939 Impact factor: 20.441
Results of SARS CoV2 tests in travelers attending the CAPV. December 16th, 2021–January 31st, 2022.
| Total n (%) | ||||
|---|---|---|---|---|
| NEGATIVE n (%) | POSITIVE n (%) | |||
| Test type | ANTIGEN | 3876 (90.7) | 397 (9.3) | 4273 (100) |
| PCR | 786 (87.0) | 117 (13.0) | 903 (100) | |
| Total | 4662 (90.1) | 514 (9.9) | 5176 (100) | |
Chi squared dist. p = 0.001.
Demographic characteristics of the travelers attending the CAPV for SARS CoV2 tests. December 16th, 2021 to January 31st, 2022.
| Number | Percentage | ||
|---|---|---|---|
| Less than 20 | 856 | 16.5 | |
| 20 to 29 | 1022 | 19.7 | |
| 30 to 39 | 1144 | 22.1 | |
| 40 to 49 | 854 | 16.5 | |
| 50 to 59 | 795 | 15.4 | |
| 60 and more | 505 | 9.8 | |
| Total | 2332 | 100,0 | |
| FEMALE | 2509 | 48.5 | |
| MALE | 2667 | 51.1 | |
| Total | 2332 | 100,0 | |
| Mexico | 2965 | 57.3 | |
| EEUU | 1539 | 29.7 | |
| Europe | 276 | 5.3 | |
| Rest of America | 263 | 5.1 | |
| Another country | 133 | 2.6 | |
| Total | 5176 | 100 | |
| EMIGRATION/RETURNING HOME | 1924 | 37.2 | |
| STUDIES | 153 | 3 | |
| BUSINESS | 187 | 3.6 | |
| TOURISM | 2116 | 40.9 | |
| OTHER | 796 | 15.4 | |
| Total | 5176 | 100 | |
| NORTH AMERICA | 3953 | 76.4 | |
| EUROPE | 603 | 11.6 | |
| OTHER | 620 | 12 | |
| Total | 2332 | 100,0 |
Suggestive symptoms of COVID-19 and test results in travelers attending the CAPV. December 16th, 2021 to January 31st, 2022.
| Number | Percentage | ||
|---|---|---|---|
| COVID-19 suggestive symptoms | None | 4918 | 95.0 |
| One symptom | 168 | 3.2 | |
| Two symptoms | 63 | 1.2 | |
| Three or more | 27 | ,6 | |
| Total | 2332 | 100,0 | |
| NEGATIVE | 4662 | 90.1 | |
| POSITIVE | 514 | 9.9 | |
| Total | 2332 | 100,0 | |
| No case of COVID-19 | 4662 | 90.1 | |
| Asymptomatic case | 399 | 7.7 | |
| Symptomatic case | 115 | 2.2 | |
| Total | 2332 | 100,0 | |
Distribution of COVID-19 cases according to symptoms and demographic characteristics in travelers attending the CAPV CDMX. December 16th, 2021 to January 31st, 2022.
| No case | Asymtomatic | Symptomatic | Total | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Number | % | Number | % | Number | % | Number | % | ||
| Gender | Female | 2255 | 89.9% | 189 | 7.5% | 65 | 2.6% | 2509 | 100.0% |
| Male | 2407 | 90.3% | 210 | 7.9% | 50 | 1.9% | 2667 | 100.0% | |
| p value = 0.202 | |||||||||
| Less than 20 | 780 | 91.1% | 68 | 7.9% | 8 | 0.9% | 856 | 100.0% | |
| 20 to 29 | 937 | 91.7% | 63 | 6.2% | 22 | 2.2% | 1022 | 100.0% | |
| 30 to 39 | 1022 | 89.3% | 82 | 7.2% | 40 | 3.5% | 1144 | 100.0% | |
| 40 to 49 | 753 | 88.2% | 78 | 9.1% | 23 | 2.7% | 854 | 100.0% | |
| 50 to 59 | 714 | 89.8% | 68 | 8.6% | 13 | 1.6% | 795 | 100.0% | |
| 61 nad over | 456 | 90.3% | 399 | 7.7% | 115 | 2.2% | 505 | 100.0% | |
| p value = 0.006 | |||||||||
| Nationality | Mexico | 2577 | 86.9% | 275 | 9.3% | 113 | 3.8% | 2965 | 100.0% |
| EEUU | 1463 | 95.1% | 76 | 4.9% | 0 | 0.0% | 1539 | 100.0% | |
| Europe | 266 | 96.4% | 9 | 3.3% | 1 | 0.4% | 276 | 100.0% | |
| Rest of America | 236 | 89.7% | 26 | 9.9% | 1 | 0.4% | 263 | 100.0% | |
| Other | 120 | 90.2% | 13 | 9.8% | 0 | 0.0% | 133 | 100.0% | |
| p value = 0.001 | |||||||||
| Reason | Emigration/returning home | 1826 | 94.9% | 96 | 5.0% | 2 | 0.1% | 1924 | 100.0% |
| Studies | 143 | 93.5% | 10 | 6.5% | 0 | 0.0% | 153 | 100.0% | |
| Business | 180 | 96.3% | 7 | 3.7% | 0 | 0.0% | 187 | 100.0% | |
| Tourism | 1951 | 92.2% | 146 | 6.9% | 19 | 0.9% | 2116 | 100.0% | |
| Other | 562 | 70.6% | 140 | 17.6% | 94 | 11.8% | 796 | 100.0% | |
| p value = 0.001 | |||||||||
| North America | 3538 | 89.5% | 324 | 8.2% | 91 | 2.3% | 3953 | 100.0% | |
| Europe | 579 | 96.0% | 24 | 4.0% | 0 | 0.0% | 222 | 100.0% | |
| Other | 545 | 87.9% | 51 | 8.2% | 24 | 3.9% | 620 | 100.0% | |
| p value = 0.001 | |||||||||
| 4662 | 90.1% | 399 | 7.7% | 115 | 2.2% | 5176 | 100.0% | ||
Fig. 1Proportion of COVID-19 cases according to age group and symptoms. CAPV December 16, 2021–January 31, 2022.